{"id":478708,"date":"2020-04-09T14:04:01","date_gmt":"2020-04-09T14:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=478708"},"modified":"2020-04-09T14:04:01","modified_gmt":"2020-04-09T14:04:01","slug":"alzheimers-disease-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-market-insights-epidemiology-and-market-forecast2030_478708.html","title":{"rendered":"Alzheimer’s disease Market Insights, Epidemiology, and Market Forecast-2030"},"content":{"rendered":"
\"Alzheimer\\'s<\/a><\/div>\n

(Albany, US) DelveInsight has launched a new report on Alzheimer’s disease Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Alzheimer’s disease (AD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Alzheimer’s disease (AD), historical and forecasted epidemiology as well as the Alzheimer’s disease (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Alzheimer’s disease (AD) market report provides current treatment practices, emerging drugs, Alzheimer’s disease (AD) market share of the individual therapies, current and forecasted Alzheimer’s disease (AD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alzheimer’s disease (AD) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently) accounting for ~60–80% of cases. The exact cause of Alzheimer’s disease is unknown, although a number of things are thought to increase your risk of developing the condition. These include increasing age, a family history of the condition, previous severe head injuries, and lifestyle factors and conditions associated with cardiovascular disease. The most common early symptom of Alzheimer’s is difficulty remembering newly learned information because Alzheimer’s changes typically begin in the part of the brain that affects learning.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- free sample page<\/a><\/strong><\/em><\/p>\n

Epidemiology<\/strong><\/em><\/p>\n

The Alzheimer’s disease (AD) epidemiology division provide insights about historical and current Alzheimer’s disease (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/em><\/p>\n

Report key facts:- <\/em><\/p>\n

1.  <\/em>According to a review article entitled “Alzheimer Disease<\/em>” by Liana<\/em>G.<\/em>Apostolova<\/em>et al., <\/em>one nationally representative US data set, the Aging, Demographics, and Memory Study (ADAMS), estimated that in the United States, 14% of people of 71 years and older have dementia. Alzheimer’s Disease (AD) accounted for 70% of the dementia cases across the age spectrum in this cohort [2016].<\/p>\n

2.   Alzheimer<\/em>Europe<\/em>estimates the number of people with dementia in Germany in 2012 as being 1.92% of the total population. The number of people with dementia as a percentage of the population is somewhat higher than the EU average of 1.55%.<\/p>\n

3. According to Alzheimer’s Association, the percentage of people with Alzheimer’s dementia increases with age: <5% of people aged 65-74, <20% of people aged 75-84, and >30% and <50% of people aged 85 and older have Alzheimer’s dementia. Out of these more than 50% are aged 75 or older [2018]<\/p>\n

Key companies are working on this disease that are given below:- <\/strong><\/em> <\/strong><\/em><\/p>\n

1. Lohmann Therapie- Systeme\/ Novartis Pharma Co.
2. Green Valley Pharmaceuticals.
3. AgeneBio<\/p>\n

Name of drugs covered are given below:-<\/strong><\/em><\/p>\n

1. Exelon
2.Oligomannate
3. AGB101<\/p>\n

Table of content<\/strong><\/em><\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Alzheimer’s disease (AD)<\/span><\/p>\n

3. Competitive Intelligence Analysis for Alzheimer’s disease (AD)<\/span><\/p>\n

4. Alzheimer’s disease (AD): Market Overview at a Glance<\/span><\/p>\n

4.1. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Alzheimer’s disease (AD): Disease Background and Overview<\/span><\/p>\n

5.1. Introduction<\/span><\/p>\n

5.2. Sign and Symptoms <\/span><\/p>\n

5.3. Pathophysiology <\/span><\/p>\n

5.4. Risk Factors <\/span><\/p>\n

5.5. Diagnosis <\/span><\/p>\n

6. Patient Journey<\/span><\/p>\n

7. Alzheimer’s disease (AD) Epidemiology and Patient Population<\/span><\/p>\n

7.1. Epidemiology Key Findings<\/span><\/p>\n

7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

7.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n

7.4. United States Epidemiology<\/span><\/p>\n

7.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

7.5.1. Germany Epidemiology<\/span><\/p>\n

7.5.1.1. Alzheimer’s disease (AD) Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n

7.5.2. France Epidemiology<\/span><\/p>\n

7.5.2.1. Alzheimer’s disease (AD) Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n

7.5.3. Italy Epidemiology<\/span><\/p>\n

7.5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n

7.5.4. Spain Epidemiology<\/span><\/p>\n

7.5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n

7.5.5. United Kingdom Epidemiology<\/span><\/p>\n

7.5.5.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

7.5.6. Japan Epidemiology<\/span><\/p>\n

7.5.6.1. Alzheimer’s disease (AD) Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

8.1. Alzheimer’s disease (AD) Treatment and Management<\/span><\/p>\n

8.2. Alzheimer’s disease (AD) Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Alzheimer’s disease (AD) Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

11.1. List of Marketed Products in the 7MM<\/span><\/p>\n

11.2. Drug Name: Company Name<\/span><\/p>\n

11.2.1. Product Description<\/span><\/p>\n

11.2.2. Regulatory Milestones<\/span><\/p>\n

11.2.3. Other Developmental Activities<\/span><\/p>\n

11.2.4. Pivotal Clinical Trials<\/span><\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

12. Emerging Therapies<\/span><\/p>\n

12.1. Key Cross<\/span><\/p>\n

12.2. Drug Name: Company Name<\/span><\/p>\n

12.2.1. Product Description<\/span><\/p>\n

12.2.2. Other Developmental Activities<\/span><\/p>\n

12.2.3. Clinical Development<\/span><\/p>\n

12.2.4. Safety and Efficacy<\/span><\/p>\n

12.2.5. Product Profile<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

13. Alzheimer’s disease (AD): Seven Major Market Analysis<\/span><\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Alzheimer’s disease (AD) Market Size in 7MM<\/span><\/p>\n

13.3. Alzheimer’s disease (AD) Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

15.1. United States: Market Size<\/span><\/p>\n

15.1.1. Alzheimer’s disease (AD) Total Market Size in the United States<\/span><\/p>\n

15.1.2. Alzheimer’s disease (AD) Market Size by Therapies in the United States<\/span><\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n

15.3. Germany Market Size<\/span><\/p>\n

15.3.1. Alzheimer’s disease (AD) Total Market Size in Germany<\/span><\/p>\n

15.3.2. Alzheimer’s disease (AD) Market Size by Therapies in Germany<\/span><\/p>\n

15.4. France Market Size<\/span><\/p>\n

15.4.1. Alzheimer’s disease (AD) Total Market Size in France<\/span><\/p>\n

15.4.2. Alzheimer’s disease (AD) Market Size by Therapies in France<\/span><\/p>\n

15.5. Italy Market Size<\/span><\/p>\n

15.5.1. Alzheimer’s disease (AD) Total Market Size in Italy<\/span><\/p>\n

15.5.2. Alzheimer’s disease (AD) Market Size by Therapies in Italy<\/span><\/p>\n

15.6. Spain Market Size<\/span><\/p>\n

15.6.1. Alzheimer’s disease (AD) Total Market Size in Spain<\/span><\/p>\n

15.6.2. Alzheimer’s disease (AD) Market Size by Therapies in Spain<\/span><\/p>\n

15.7. United Kingdom Market Size<\/span><\/p>\n

15.7.1. Alzheimer’s disease (AD) Total Market Size in the United Kingdom<\/span><\/p>\n

15.7.2. Alzheimer’s disease (AD) Market Size by Therapies in the United Kingdom<\/span><\/p>\n

15.8. Japan Market Outlook<\/span><\/p>\n

15.8.1. Japan Market Size<\/span><\/p>\n

15.8.2. Alzheimer’s disease (AD) Total Market Size in Japan<\/span><\/p>\n

15.8.3. Alzheimer’s disease (AD) Market Size by Therapies in Japan<\/span><\/p>\n

16. Access and Reimbursement Overview of Alzheimer’s disease (AD)<\/span><\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/em><\/p>\n